Latest News Nicox Reports Fourth Quarter 2021 and Full-Year Revenue Slump By Staff Monday, January 24, 2022 12:21 AM SOPHIA ANTIPOLIS, France—Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, reported net revenue of €3.5 million for the fourth quarter of 2021 ended Dec. 31, 2021, versus net revenue of €5.8 million for the fourth quarter of 2020. Net revenue for 2021 was €7.2 million versus €12.9 million in 2020. The results included the Nicox Group, a subsidiary. At the end of the fourth quarter, the Nicox Group had cash and cash equivalents of €41.9 million as compared with €32.7 million at Sept. 30, 2021 and €47.2 million at Dec. 31, 2020. The company is financed until fourth quarter 2023, financing development of a glaucoma drug, NCX 470, only. As of Dec. 31, 2021, the Nicox Group had financial debt of €18.3 million consisting of €16.3 million in the form of a bond financing agreement with Kreos Capital signed in January 2019 and a €2.0 million credit agreement guaranteed by the French State in August 2020 in the context of the COVID-19 pandemic. The company recently raised €15 million in a private placement and concurrently restructured the bond financing agreement with Kreos Capital, extending the cash runway to the fourth quarter of 2023. Only the figure related to the cash position of the Nicox Group as of Dec. 31, 2020 is audited; all other financial figures are non-audited and subject to change on completion of audit procedures, the company said.